The Effect of miR-361-3p Targeting TRAF6 on Apoptosis of Multiple Myeloma Cells

Zhen Fan1, Zhiwei Wu1, Bo Yang1

  • 1Department of Hematology, The First People's Hospital of Jingmen, No. 67 Xiangshan Avenue, Jingmen, Hubei Province 448000, P.R. China.

Insights

microRNA-361-3p (miR-361-3p) is downregulated in multiple myeloma (MM). Upregulating miR-361-3p inhibits MM cell growth and promotes apoptosis by targeting TRAF6, suggesting its therapeutic potential.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • microRNA-361-3p (miR-361-3p) has known roles in various cancers, but its function in multiple myeloma (MM) is under-investigated.
  • Understanding miR-361-3p's role in MM is crucial for identifying novel therapeutic targets.

Purpose of the Study:

  • To investigate the expression and function of miR-361-3p in multiple myeloma (MM).
  • To explore the potential of miR-361-3p as a therapeutic agent for MM.

Main Methods:

  • Quantitative real-time PCR to measure miR-361-3p and TRAF6 expression in MM patients and cell lines.
  • Cell viability assays (MTT), colony formation assays, and apoptosis assays (flow cytometry) to assess MM cell behavior.
  • Bioinformatic prediction (TargetScan) and rescue experiments to elucidate the miR-361-3p/TRAF6 interaction.

Main Results:

  • miR-361-3p was significantly downregulated in MM patient plasma and cell lines.
  • Overexpression of miR-361-3p inhibited MM cell viability and colony formation while promoting apoptosis.
  • TRAF6, a predicted target of miR-361-3p, was upregulated in MM and its effects were opposite to miR-361-3p.
  • miR-361-3p suppressed MM progression by targeting TRAF6, impacting apoptosis-related genes like Bcl-2, Bax, and Cleaved caspase-3.

Conclusions:

  • miR-361-3p acts as a tumor suppressor in multiple myeloma.
  • Targeting miR-361-3p represents a promising therapeutic strategy for multiple myeloma treatment.